![Michael Atkin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Atkin
Director Ejecutivo en
Ulysses Pharmaceuticals Products, Inc.
.
Perfil
Michael C.
Atkin is the founder of Syzent Partners Ltd. founded in 2008, where he holds the title of President.
He currently holds the positions of Executive Chairman, President & CEO at Ulysses Pharmaceuticals Products, Inc. and Director at Affinite Instruments.
Mr. Atkin's former positions include President & Chief Executive Officer at Aegera Therapeutics, Inc., President, Chief Executive Officer & Secretary at Gladius Pharmaceuticals Corp., Chairman at ChitogenX, Inc., Chairman at Sopharmia, Inc., Director at Genizon Biosciences, Inc., Director at Topigen Pharmaceuticals, Inc., and Principal at Bristol Myers Squibb Co. He also held the position of Vice President-Business Development at Lederle International.
Mr. Atkin received his undergraduate degree from the University of Kent and his MBA from Columbia Business School.
Cargos activos de Michael Atkin
| Empresas | Cargo | Inicio |
|---|---|---|
Ulysses Pharmaceuticals Products, Inc.
 Ulysses Pharmaceuticals Products, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops antibiotics for empiric monotherapy to control resistant bacterial infections | Director Ejecutivo | - |
Syzent Partners Ltd. | Fundador | 01/01/2008 |
Affinite Instruments | Director/Miembro de la Junta | - |
Antiguos cargos conocidos de Michael Atkin.
| Empresas | Cargo | Fin |
|---|---|---|
| CHITOGENX INC. | Presidente | 01/07/2022 |
Gladius Pharmaceuticals Corp.
 Gladius Pharmaceuticals Corp. BiotechnologyHealth Technology Operates as biotechnology firm | Director Ejecutivo | 01/01/2019 |
Genizon Biosciences, Inc.
 Genizon Biosciences, Inc. BiotechnologyHealth Technology Provides drug development services | Director/Miembro de la Junta | 30/05/2012 |
Sopharmia, Inc. | Presidente | - |
Lederle International | Corporate Officer/Principal | - |
Formación de Michael Atkin.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
3
Relaciones de 1er grado
13
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 13 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Genizon Biosciences, Inc.
Genizon Biosciences, Inc. BiotechnologyHealth Technology Provides drug development services | Health Technology |
Aegera Therapeutics, Inc.
 Aegera Therapeutics, Inc. BiotechnologyHealth Technology Manufactures and develops drugs | Health Technology |
Topigen Pharmaceuticals, Inc.
 Topigen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for respiratory diseases | Health Technology |
Lederle International | |
Ulysses Pharmaceuticals Products, Inc.
Ulysses Pharmaceuticals Products, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops antibiotics for empiric monotherapy to control resistant bacterial infections | Health Technology |
University of Kent
 University of Kent Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Columbia Business School
 Columbia Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Gladius Pharmaceuticals Corp.
Gladius Pharmaceuticals Corp. BiotechnologyHealth Technology Operates as biotechnology firm | Health Technology |
ChitogenX, Inc.
 ChitogenX, Inc. BiotechnologyHealth Technology Operates as a development stage biotechnology company | Health Technology |
Syzent Partners Ltd. | |
Sopharmia, Inc. | |
Affinite Instruments |
- Bolsa de valores
- Insiders
- Michael Atkin
